At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Bevacizumabbiological
Likely dose
Bevacizumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab for Sarcoma. Completed, enrolled 32 participants across 5 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedFeb 2006
Primary CompletionJun 2013
Study CompletionNov 2016
TodayJul 2026
First PostedFeb 7, 2006
Enrollment StartOct 1, 2005
Primary CompletionJun 6, 2013
Study CompletionNov 10, 2016
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 20.4 years ago
Interventions
Bevacizumabbiological
Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).